MARPLAN
LOE Approachingisocarboxazid
NDAORALTABLET
Approved
Jul 1959
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Drug data last refreshed 4h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MARPLAN (isocarboxazid) is an oral monoamine oxidase inhibitor (MAOI) approved in 1959 for the treatment of depression, particularly atypical and refractory cases. It works by inhibiting the enzyme monoamine oxidase, increasing levels of neurotransmitters such as serotonin, dopamine, and norepinephrine in the central nervous system. This legacy antidepressant remains a niche therapeutic option for patients who have failed trials of more commonly used agents.
$0.349MPart D
LOE ApproachingWith less than $350K in annual Part D spending and an approaching loss of exclusivity, MARPLAN is a niche legacy product with minimal commercial team expansion potential.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on MARPLAN offers limited career advancement opportunity given its niche market position, minimal spending ($349K), and lack of commercial momentum. Career value lies primarily in specialized medical affairs, psychiatry liaison roles, or regulatory expertise rather than high-visibility commercial growth.
Medical Science Liaison (niche practice)Specialty Psychiatry Field Representative
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.